Blog, News and Events

24 July 2023

Selecting the best model for preclinical hepatitis studies

How can humanized liver models provide accurate efficacy measurements at each stage of the viral lifecycle? Hepatitis B is a serious global health threat. Around 1.5 million hepatitis B virus (HBV) infections were identified in 2019 alone and around 296 million people are thought to be living with the chronic disease.¹ Researchers are now targeting previously unexplored areas of the viral lifecycle to get closer to developing a complete cure.

PXB-mouse, Blog

10 July 2023

How PXB-mice with humanized livers enable better translational outcomes for gene-based therapeutics

In recent years, we have seen an explosion in the number of adeno-associated virus (AAV) vector-based gene therapies progressing to clinical trial stages, and subsequently an increasing number of regulatory successes. The reasons for this are clear. The versatility of AAV-based platforms makes them prime technology for targeting a range of tissues and pathologies, through their ability to silence, replace or modify genes.

PXB-mouse, Blog

27 June 2023

Humanized liver mouse models translation of antivirals for HBV and HDV

Generating high-quality, pre-clinical data is always challenging, but it is especially so when developing therapeutics for hepatitis B and D. Since Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV) only infect human hepatocytes, conventional animal models instantly pose a challenge as the entire viral lifecycle cannot be observed, and the data often doesn’t translate well to the human environment. These issues can lead to misleading metabolism, pharmacokinetics, efficacy and hepatotoxicity data, which can result in wasted time, money and resources and, potentially, failure at clinical trial stages.

PXB-mouse, Blog

3 January 2022

Targeting NASH Drug Development with a New Humanized Liver NASH Model

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries, with an estimated incidence of around 25% worldwide.

PXB-mouse, News, Blog

9 August 2021

Chimeric Mouse with Humanized Liver Consortium Publications

As the liver is the primary site for drug metabolism, the PXB-mouse is the best available model to predict human-specific metabolism prior to clinical trials. Two Studies performed with the support of PhoenixBio through the Chimeric Mouse with Humanized Liver (CMHL) Consortium are highlighted below.

PXB-mouse, Information

1 April 2021

PhoenixBio Announces Partnership with Inotiv

PhoenixBio Co., Ltd. (“PhoenixBio”) announced today that it has entered into an agreement to partner with Inotiv, Inc. (“Inotiv”) in providing pre-clinical research services utilizing the PXB-mouse® (cDNA-uPA/SCID mouse model with a humanized liver).

PXB-mouse, Information, Press Releases, News

1 February 2021

Rare Disease Day: OTCD is a Rare Disease

Rare Disease Day takes place on the last day of February each year since 2008. The main objective of Rare Disease Day is to raise awareness about rare diseases and the impact they have on lives.

PXB-mouse, Information, Blog